The present invention relates to antimicrobial compositions and methods for their use. In particular, the compositions comprise an antimicrobial agent and a nanostructured liquid crystal carrier, wherein the antimicrobial agent is contained within the nanostructured liquid crystal carrier, and wherein the nanostructured liquid crystal carrier potentiates the activity of the antimicrobial agent. Antimicrobial agents encompassed by the present invention include cationic antibiotics, antimicrobial peptides, and antifungal agents. Nanostructured liquid crystal carriers encompassed by the present invention include those formed from an amphiphilic lipid such as monoolein and phytantriol. Antimicrobial compositions encompassed by the present invention can be used for the treatment or prevention of a microbial infection, such as that caused by a Gram-negative bacterium, including where the microbial infection forms part of a biofilm. The present invention also relates to methods for reducing the viability of a microorganisms, for potentiating the activity of an antimicrobial agent, for reducing the dose of an antimicrobial agent required to treat or prevent a microbial infection, or for increasing the potency of an antimicrobial agent required to treat or prevent a microbial infection, by administering an antimicrobial composition described herein. Kits comprising the antimicrobial compositions are also encompassed by the present invention.

The present invention relates to an external preparation that is well retained on a living body surface and is capable of increasing drug permeability, in particular, an external preparation comprising a non-lamellar liquid crystal-forming lipid and a drug.

Giant multi-lamellar vesicles (GMVs) comprising lecithin are provided which are at least about 3 μm in size. Methods for preparing the GMVs, and for preparing large unilamellar vesicles (LUVs) from the GMVs, are provided, as well as methods for encapsulating cargo within the GMVs and LUVs. The present vesicles are useful for the oral delivery of encapsulated cargo.

The present invention relates to compositions forming a low viscosity mixture of:

TABLE-US-00001 a) 20-80 wt. % of at least one diacyl glycerol and/or a tocopherol; b) 20-80 wt. % of at least one phosphatidyl choline (PC); c) 5-20 wt. % of at least one biocompatible, organic mono-alcoholic solvent; d) up to 20 wt. % polar solvent e) at least one peptide active agent; f) optionally at least one antioxidant;
wherein the ratio of components a:b is in the range 40:60 to 54:46;
wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid.

The invention further relates to methods of treatment comprising administration of such compositions, and to pre-filled administration devices and kits containing the formulations.

The present invention relates to a composition comprising triglycerides, surfactant, self-assembled structures and vitamin A or provitamin A. Further aspects of the invention are a food product, the use of a composition comprising triglycerides, surfactant and self-assembled structures to stabilize vitamin A or provitamin A and a process for preparing a stabilized vitamin A or provitamin A composition.

The present application is directed to a cochleate composition including one or more cochleates and at least two antifungal compounds selected from amphotericin B, 5-flucytosine, fluconazole, ketoconazole, ravuconazole, albaconazole, itraconazole, posaconazole, isavuconazole and/or voriconazole. Methods of using the antifungal cochleate formulations are also disclosed.

The present invention provides novel, stable lipid particles having a non-lamellar structure and comprising one or more active agents or therapeutic agents, methods of making such lipid particles, and methods of delivering and/or administering such lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) that have a non-lamellar structure and that comprise a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.

Provided are aromatic oligoamide foldamers and self-assembled compositions of the same. The aromatic oligoamide foldamers and compositions can form tube-like structures that can form pores in membranes. The pores can be used to transport ions and molecules, such as, for example, cryoprotective agents or therapeutic agents, through the membrane. The tube-like structures exhibit desirable stability at low temperatures.

The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent;
wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.

The invention provides a compartmentalised gel matrix comprising one or more compartments, wherein each compartment comprises a volume of hydrophobic medium and one or more aqueous droplets therein. The invention further provides a pharmaceutical formulation comprising a compartmentalised gel matrix according to the invention, a synthetic cell comprising a compartmentalised gel matrix according to the invention and a synthetic tissue comprising a compartmentalised gel matrix according to the invention.